KPRX

KIORA PHARMACEUTICALS INC KPRX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $16.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-2.08M

Quarter to Jun 30

Free cash flow

$-1.92M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.91M total
PERCEPTIVE ADVISORS LLC
$1.15MNew
ADAR1 Capital Management, LLC
$441.7K0.0%
CITADEL ADVISORS LLC
$305.1K+134.2%
TWO SIGMA INVESTMENTS, LP
$233.5KNew
MILLENNIUM MANAGEMENT LLC
$195.2KNew
HRT FINANCIAL LP
$154.0KNew
RENAISSANCE TECHNOLOGIES LLC
$78.4KNew
GEODE CAPITAL MANAGEMENT, LLC
$70.3K-44.2%
VANGUARD CAPITAL MANAGEMENT LLC
$52.2K0.0%
Scientech Research LLC
$49.3KNew
VANGUARD FIDUCIARY TRUST CO
$34.3K0.0%
LPL Financial LLC
$32.9KNew
DIMENSIONAL FUND ADVISORS LP
$31.9KNew
NORTHERN TRUST CORP
$30.9KNew
JANE STREET GROUP, LLC
$27.9KNew
UBS Group AG
$5.2K+50.7%
Caitong International Asset Management Co., Ltd
$4.8KNew
MORGAN STANLEY
$3.7K0.0%
Tower Research Capital LLC (TRC)
$2.2K-15.9%
SBI Securities Co., Ltd.
$6730.0%
BlackRock, Inc.
$1530.0%
Activest Wealth Management
$50.0%
See all 22 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/KPRX

Earnings Per Share

13fpro.ai/company/KPRX

Loading ratio trend…

KPRX key financials by period

Reported revenue, net income and operating margin by fiscal year, from KIORA PHARMACEUTICALS INC's annual filings on SEC EDGAR.

KIORA PHARMACEUTICALS INC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$16.0M$3.6M28.1%
FY 2020$12.1K$-6.9M—
FY 2019$2.7M$-7.1M—
FY 2018$1.7M$-10.8M—
FY 2017$407.5K$-13.2M—
FY 2016$669.3K$-13.3M—
Source: KPRX filings on SEC EDGAR →

KPRX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About KIORA PHARMACEUTICALS INC (KPRX): stock profile, AI score and financials

KIORA PHARMACEUTICALS INC (KPRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. KPRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $16.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), KIORA PHARMACEUTICALS INC reports net income of $-2.1M, free cash flow of $-1.9M. Top institutional holders of KPRX by reported 13-F value include PERCEPTIVE ADVISORS, ADAR1 Capital Management, CITADEL ADVISORS, based on the most recent SEC filings. KPRX trades on the Nasdaq exchange and files with the SEC under CIK 1372514. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KIORA PHARMACEUTICALS INC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1372514 →